Skip to main content
SEOUL PHARMA CO.,LTD logo

SEOUL PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 018680 ISIN · KR7018680009 KO Manufacturing
Open in API
Filings indexed 151 across all filing types
Latest filing 2025-03-20 Audit Report / Informat…
Country KR South Korea
Listing KO 018680

About SEOUL PHARMA CO.,LTD

http://www.seoulpharmaceuticals.com/

Seoul Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products. The company specializes in innovative drug delivery systems, with a core competency in Orally Disintegrating Film (ODF) technology. Its product portfolio includes a wide range of prescription and over-the-counter medications. Key therapeutic areas cover cardiovascular and respiratory systems, as well as anti-infective agents such as antibacterials, antifungals, and antivirals. The company also produces vitamins and antibiotics, aiming to improve health outcomes through its cutting-edge technological capabilities.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal filing titled '감사보고서 제출' (Submission of Audit Report) submitted by Seoul Pharma. It provides the audit opinion (unqualified/proper), key financial data, and details regarding the auditor (Samil PwC). While it contains financial data, it is a specific regulatory disclosure regarding the submission of the audit report itself, which falls under the 'Audit Report / Information' category as it provides the results of the audit process. FY 2024
2025-03-20 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Seoul Pharma (주식회사 서울제약) for the fiscal year ending December 31, 2024. It includes the independent auditor's opinion from Samil PricewaterhouseCoopers, detailed financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and extensive notes to the financial statements. While it contains financial data, it is specifically the formal audit report required by regulatory standards, which is distinct from a standard 10-K or Interim Report. Based on the provided definitions, 'Audit Report / Information' (AR) is the most accurate classification. FY 2024
2025-03-20 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of an Annual General Meeting (AGM) and a subsequent correction filing regarding the details of a director/auditor appointment. It outlines the agenda, meeting date, location, and specific voting items (financial statements, board appointments, and compensation limits). This falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on matters at the upcoming meeting.
2025-03-17 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Seoul Pharma. It outlines the date, location, agenda items (such as financial statement approval, director/auditor appointments, and remuneration limits), and details regarding the board's resolution. This type of document is a standard proxy solicitation or notice of meeting material sent to shareholders to inform them of upcoming voting items, which falls under the Proxy Solicitation & Information Statement category.
2025-03-13 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Seoul Pharma. It contains the agenda for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and remuneration limits. While it contains financial data, it is a formal notice and proxy-related material sent to shareholders to solicit their attendance and voting, which fits the definition of a Proxy Solicitation & Information Statement (PSI).
2025-03-13 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with other companies' meetings. Since this is a regulatory disclosure regarding meeting logistics and compliance with corporate governance standards rather than the meeting materials themselves or a report publication announcement, it falls under the general regulatory filing category.
2025-03-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.